Wednesday , March 29 2017
Home / Immune Deficiencies

Immune Deficiencies

BPL’s Gammaplex Wins FDA Approval for Treatment of PI and CITP

ELSTREE, UK AND DURHAM, NC – FEBRUARY 7, 2017 – Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Gammaplex® 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and …

Read More »

Amgen and Immatics Partner To Develop Novel Bispecific Cancer Immunotherapies

THOUSAND OAKS, Calif. and TUEBINGEN, Germany, Jan. 9, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Immatics’ world-leading …

Read More »

FDA Approves Shire’s Cuvitru for Treatment of Primary Immunodeficiency

Lexington, Mass. – September 14, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted approval for CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older. CUVITRU is a treatment for …

Read More »

Kedrion Biopharma Expands Immunoglobulin Therapies Portfolio, Gains Commercial Rights in the U.S. to BIVIGAM®, a Recently Approved IGIV Brand

Kedrion Biopharma Inc., established in the U.S. market in 2011, is an emerging player in the rare disease arena The Company aims to build business rapidly through ongoing organic growth of its brand portfolio and strategic partnerships with other industry leaders Gaining rights to commercialize BIVIGAM® [Immune Globulin Intravenous (Human), …

Read More »

Baxter, Mayo Clinic and VPD Form Vitesse Biologics to Accelerate Drug Development

In an effort to accelerate therapeutic innovation, Baxter Ventures, the Mayo Clinic and Velocity Pharmaceutical Development (VPD) have teamed up to form a new company called Vitesse Biologics, LLC. The formation of Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and …

Read More »

CSL Behring’s Kcentra Shows Superiority to Plasma in Late-Stage Study

Results from CSL Behring’s late-stage study showing Kcentra’s superiority to plasma for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, warfarin) therapy in adult patients needing an urgent surgery or invasive procedure were published in The Lancet. CSL’s Kcentra is the first and …

Read More »

Incyte and Agenus Partner for Development of Immuno-Oncology Products

Incyte and Agenus will partner on immuno-oncology targets in a deal worth up to $410 million. The companies announced today that they have entered into a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocycle Display antibody discovery platform. According to terms of the deal, …

Read More »